Syros Pharmaceuticals Inc received notice from Pfizer Inc (NYSE: PFE), as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated December 17, 2019, related to the discovery, development, a
The FDA approved BD's (Becton, Dickinson, and Company) (NYSE: BDX) BD Alaris Infusion System with 510(k) clearance, which enables both remediation and a return to full commercial operations for the most comprehensive